Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

The panel of experts in lung cancer examines genetic alterations affecting treatment response and biomarker testing rates in metastatic non-small cell lung cancer (mNSCLC).

EP: 1.Biomarker Testing and Guideline-Recommended Care in mNSCLC

EP: 2.Strategies to Increase Biomarker Testing Rates

EP: 3.Limitations on Optimal Biomarker Testing Rates

EP: 4.Impact of Biomarker Testing on Treatment Selection and Outcomes

EP: 5.Key Challenges and Unmet Needs in Newly Diagnosed Driver-Negative mNSCLC

EP: 6.NCCN Recommendations by PD-L1 Expression Level

EP: 7.Limitations of NCCN PD-L1 Expression Recommendations

EP: 8.Emerging Data and Evidence for Dual Immunotherapy plus Chemotherapy in First-Line mNSCLC

Now Viewing

EP: 9.Genetic Alterations Impacting Treatment Response and Biomarker Testing Rates in mNSCLC

EP: 10.Molecular Characteristics Beyond Mutations Influencing Immunotherapy Response

EP: 11.Clinical Factors Impacting Immunotherapy Response and Optimizing Patient Selection

EP: 12.Overcoming Immunotherapy Resistance: Identifying Non-Responders and Novel Approaches

EP: 13.Key Takeaways on Enhancing Outcomes for mNSCLC Without Targetable Driver Mutations

Video content above is prompted by the following:

How do mutations associated like STK11, KEAP1, KRAS impact effectiveness of standard therapies and confer resistance?
In real-world clinical practice, how frequently do patients with mNSCLC undergo comprehensive molecular and biomarker testing through techniques like NGS to evaluate for genetic alterations and potential targetable mutations?